A decision-ready blueprint
A business development and partnering solution designed around the commercial realities of life science vc & investment firms.
Scientific, commercial, and digital architecture, with specialist expertise assembled where the engagement requires it.
Biotech investment teams need a clear way to connect scientific, commercial, contractual, and market evidence to the partnering and value-creation decisions across a portfolio. The useful question is rarely whether an asset has information available. It is whether the relevant evidence, assumptions, risks, and owners can be brought together for a timely investment or partner discussion.
Lonrú Consulting designs business-development and partnering architecture around that work. We build controlled workflows for partner landscape assessment, transaction preparation, portfolio scenario analysis, and the decision tools that make a fund's next priority easier to assess.
We define the scientific, commercial, financial, contractual, portfolio, and market sources relevant to the selected value-creation or transaction question, together with permissions and evidence boundaries.
Configured systems can structure diligence material, compare defined partner or transaction terms, prepare scenario inputs, and support repeatable analysis within the agreed context.
Lonrú provides principal-led strategy, transaction framing, and review governance. Investment, scientific, legal, operating, and client-selected specialist reviewers can be assigned according to the fund's decision process.
Approved outputs can be delivered through a partner landscape, transaction workspace, risk view, portfolio scenario tool, or investment-committee briefing environment.
Bring the relevant scientific, commercial, market, and contractual evidence into a defined view that supports a partner, licensing, or portfolio value-creation discussion.
Make agreed clinical, commercial, financial, and transaction assumptions visible so investment teams can test the consequences of defined changes.
Prepare a controlled view of defined terms, dependencies, and potential exposure so legal, operating, and investment owners can assess what requires attention.
Create the architecture behind selected portfolio-company partner workflows, data rooms, decision tools, or commercial interfaces where it adds value.
The architecture can make evidence, assumptions, and review needs more visible. It does not make investment recommendations, determine a valuation, or replace the fund's accountable decision-makers and governance process.
We establish the information boundaries, specialist review needs, and authority for each workstream before confidential portfolio or transaction material is used.
Relevant experience
Up to 9.2%
Engineered an AI-powered Portfolio Risk Engine to automate contract-term extraction. It identifies unlimited-liability clauses and simulates inflation impacts, reducing contract cycle time and helping prevent value leakage of up to 9.2% of annual contract value.
NPV modelling
Designed multi-dimensional pricing and Net Present Value modelling systems for cell and gene therapies, integrating clinical-trial milestones, manufacturing COG constraints, and quantified patient-benefit metrics.
Architecture in context
Diagram summary: Scientific, commercial, contractual, portfolio, and market evidence is contextualised, analysed, and tested through ActiveArchitecture™ before it supports a value-creation or transaction decision.
Practical questions
Next step
Bring the decision, workflow, or delivery constraint that needs a clearer operating path.
Request a focused briefing